PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced the completion of the expansion of its new Biotech Center of Excellence in Philadelphia, Pennsylvania, a major investment that will represent the new U.S. biologics flagship site for customers. In addition, PCI is also announcing significant new investments to expand its global packaging capabilities for biologic drug products at its operations in Ireland, complementing existing capabilities in UK and Germany. These investments will provide customers with global packaging solutions for their biologics and injectable drug products to meet growing market demands.
“Worldwide forecasts for biologics show strong growth over the next several years, and PCI is staying on top of this trend and investing in the latest technology to enhance capacity and accommodate the novel drug delivery formats of biologic products. We have already secured projects from numerous global biopharmaceutical customers that will benefit from the new expansion, which is a reflection of the market demand,” said Salim Haffar, chief executive officer, PCI Pharma Services. “PCI has a rich heritage in biologics going back more than 20 years, but we now have the opportunity to apply this expertise on a larger scale. We are looking forward to leveraging our breadth of experience with the latest technology to help our customers bring life-changing therapies to patients.”
The recent investments include partnerships with leading suppliers such as Dividella, groninger, Marchesini Group and Syntegon (formerly Bosch Packaging Technology) to provide state-of-the-art equipment for pre-filled syringe, auto-injector and vial packaging and the latest serialization technology. The expansions also include increasing high-speed automatic syringe assembly and labeling, vial labeling and cartoning, and auto-injector assembly – allowing for greater flexibility in serving customers across their supply-chain requirements. In addition to building out existing cold storage capabilities and leading-edge manufacturing suites, PCI will continue to offer innovative design teams to help address the packaging challenges often presented by biologic products.
“With these expansions, our Biotech Centers of Excellence are prepared to support the scale required to meet customers’ needs all over the world,” said Brad Payne, chief operating officer, PCI Pharma Services. “PCI has the flexibility to handle the dynamic volumes of biopharmaceutical therapies, whether large or small, catering to the needs of our global customer base. This flexibility extends to the varied capacities needed for launches, global ramp-up and ongoing supply. With these investments in high-speed automation, PCI will dramatically improve productivity as well as supply continuity and quality.”
Find out more about biologics packaging by PCI Pharma Services here.
About PCI Pharma Services
The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pci.com or follow us on Twitter at @PCI_Social.